ReviewCurrent opinion in rheumatology2013
Measuring response in the gastrointestinal tract in systemic sclerosis.
Review in Current opinion in rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors associated with development of gastrointestinal problems in patients with scleroderma: a systematic review.Systematic reviews · 2015Pooled it
- Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.Arthritis research & therapy · 2017Trial
- A distinct gastrointestinal symptom profile characterizes clinically relevant fatigue in systemic sclerosis.Clinical rheumatology · 2026Article
- Association of lipid parameters with the development of disease complications in patients with limited cutaneous systemic sclerosis: a prospective exploratory cohort study.Frontiers in nutrition · 2026Article
- Association of Inflammation-Based Ratios with Endothelial Dysfunction Markers and Clinical Parameters in Limited Cutaneous Systemic Sclerosis.Journal of clinical medicine · 2025Article
- Impact of gastrointestinal involvement on mortality and malnutrition in systemic sclerosis: an observational cohort of 135 patients.Rheumatology international · 2025Observational
- Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis.Rheumatology (Oxford, England) · 2025Article
- Characteristics of patients with systemic sclerosis with aspiration: A single-center study.Journal of scleroderma and related disorders · 2025Article
- Pain and fatigue in systemic sclerosis: Practical strategies for non-pharmacological management.Journal of scleroderma and related disorders · 2025Review
- Endothelial function and vascular events in patients with limited cutaneous systemic sclerosis (EFVELSS): a prospective observational study.Rheumatology international · 2025Observational
- Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.Clinical and experimental medicine · 2024Article
- Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?RMD open · 2024Article
- Severity and impact of digestive impairment perceived by patients with systemic sclerosis: a cross-sectional study.BMJ open · 2024Article
- Anti-Gephyrin Antibodies: A Novel Specificity in Patients With Systemic Sclerosis and Lower Bowel Dysfunction.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Gastric dysrhythmias in patients with early systemic sclerosis: a cross-sectional study.Rheumatology advances in practice · 2024Article
- Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey.ACR open rheumatology · 2024Article
- Validation of the Portuguese Version of the Scleroderma Health Assessment Questionnaire.International journal of environmental research and public health · 2023Article
- CONQUER Scleroderma: association of gastrointestinal tract symptoms in early disease with resource utilization.Rheumatology (Oxford, England) · 2023Article
- Antivinculin Antibodies in Systemic Sclerosis: Associations With Slow Gastric Transit and Extraintestinal Clinical Phenotype.Arthritis care & research · 2023Article
- The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation.Clinical and experimental rheumatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewGastrointestinal tract (GIT) involvement in systemic sclerosis (scleroderma, SSc) is the most common internal complication. This review discusses the outcome measures to capture GIT involvement in clinical care and trials. RECENT
findingsPatient-reported outcome measures have been validated (UCLA Scleroderma Clinical Trial Consortium GIT 2.0 and NIH PROMIS scales) in SSc-GIT. Multiple objective measures are available to assess mucosal involvement and motility in GIT. However, these need to be validated in SSc for trials. SUMMARY: GIT is a common cause of morbidity and has negative impact on quality of life in SSc. Recommendations are given for trial design and evaluation of GIT involvement in SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.